NIH and NASA have presented a joint competition called Quantum-Enabled Predictive Preclinical NAMs for Toxicity and Safety (QuSAFE Challenge), focused on developing quantum-sensitive technologies for preclinical drug safety research. The initiative concentrates on the application of so-called new approach methodologies (NAMs) — alternatives to traditional animal testing, including organoids and microphysiological systems (MPS). Organoids and MPS are laboratory models that reproduce the structure and function of human tissues and organs at a miniature scale. They allow for studying the body's response to pharmaceutical drugs more accurately than traditional animal models, while also reducing the ethical and practical costs associated with the use of laboratory animals. The goal of the QuSAFE Challenge is to integrate quantum sensing technologies into these systems, which should increase the sensitivity and accuracy of measurements when assessing substance toxicity. This approach is expected to enable the identification of potential health risks at earlier stages of drug development, reducing costs and time spent on clinical trials. The collaboration between NIH and NASA in this field reflects a broader trend of applying advanced technologies, originally developed for space and scientific research, to the field of biomedicine. Quantum sensors, used in the space industry for ultra-precise measurements, can find application in creating more sophisticated diagnostic and analysis tools at the cellular level. The organizers of the initiative expect that the results of the competition will contribute to the development of safer and more effective methods for testing pharmaceuticals, and will also contribute to the overall strategy of reducing the use of animals in scientific research.